13 years of historical data (2012–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cidara Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.0B | $171M | $69M | $53M | $67M | $83M | $115M | $61M | $119M | $151M | $236M |
| Enterprise Value | $6.8B | $-15570919 | $39M | $21M | $9M | $55M | $76M | $-3838701 | $54M | $56M | $129M |
| P/E Ratio → | -8.28 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5460.07 | 133.87 | 2.98 | 0.82 | 1.34 | 6.89 | 5.50 | — | — | — | — |
| P/B Ratio | 8.61 | 1.05 | — | — | 3.09 | 7.76 | 3.04 | 1.03 | 1.99 | 1.71 | 2.27 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -12.21 | 1.65 | 0.33 | 0.19 | 4.57 | 3.65 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Cidara Therapeutics, Inc. earns an operating margin of -13811.9%. Operating margins have compressed from -52.0% to -13811.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -219.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -57.9% | 100.0% | -47.4% | 100.0% | -121.9% | — | — | — | — |
| Operating Margin | -13811.9% | -13811.9% | -116.2% | -52.0% | -85.2% | -595.4% | -199.5% | — | — | — | — |
| Net Profit Margin | -13319.8% | -13319.8% | -98.5% | -52.1% | -85.7% | -597.6% | -196.5% | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -219.0% | -219.0% | — | -941.4% | -263.1% | -297.1% | -84.7% | -99.3% | -75.3% | -50.1% | -51.5% |
| ROA | -120.5% | -120.5% | -40.0% | -54.7% | -62.6% | -111.5% | -55.5% | -74.6% | -59.9% | -44.4% | -47.9% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -213.6% | -213.6% | -949.6% | -141.4% | -133.8% | -237.0% | -85.2% | -100.3% | -67.5% | -47.9% | -51.6% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $190M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | — | 0.23 | 0.74 | 0.31 | 0.17 | 0.17 | 0.11 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.14 | — | — | -2.65 | -2.61 | -1.02 | -1.09 | -1.10 | -1.08 | -1.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -274.23 | — | -100.61 | -7960.14 | -178.73 | -269.27 |
Net cash position: cash ($190M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
Cidara Therapeutics, Inc.'s current ratio of 4.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.09x to 4.25x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | 4.25 | 0.90 | 1.09 | 2.11 | 1.48 | 2.18 | 3.88 | 6.43 | 11.83 | 18.11 |
| Quick Ratio | 4.25 | 4.25 | 0.81 | 1.09 | 2.18 | 1.48 | 2.18 | 3.88 | 6.45 | 11.83 | 18.11 |
| Cash Ratio | 3.83 | 3.83 | 0.53 | 0.79 | 1.83 | 0.93 | 1.66 | 3.75 | 6.23 | 11.74 | 18.00 |
| Asset Turnover | — | 0.01 | 0.35 | 1.36 | 0.66 | 0.20 | 0.30 | — | — | — | — |
| Inventory Turnover | 6.03 | — | 6.03 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 484.95 | 254.68 | 33.04 | 39.44 | 338.02 | 0.17 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cidara Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $4M | $3M | $3M | $2M | $1M | $1M | $875043 | $724449 | $688484 |
Compare CDTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CDTXYou | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| CRMD | $559M | -23.8 | — | — | 92.7% | -51.4% | -23.2% | -46.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CDTX stacks up against sector leader BioNTech SE.
Start ComparisonCidara Therapeutics, Inc.'s current P/E ratio is -8.3x. This places it at the 50th percentile of its historical range.
Cidara Therapeutics, Inc.'s return on equity (ROE) is -219.0%. The historical average is -140.1%.
Based on historical data, Cidara Therapeutics, Inc. is trading at a P/E of -8.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cidara Therapeutics, Inc. has 100.0% gross margin and -13811.9% operating margin.